Now Enrolling Learn More Now Enrolling Learn More Now Enrolling Learn More Latest News Jul 28, 2021 Abeona Therapeutics Reports Second Quarter Financial Results View Press Release Jul 28, 2021 Abeona Therapeutics Announces Successful Type B Meeting with U.S. FDA for ABO-102 AAV-based Gene Therapy in Sanfilippo Syndrome Type A (MPS IIIA) View Press Release Jul 26, 2021 Abeona Therapeutics Announces New MRI Data Showing Increased Brain Volume in Young Patients with Sanfilippo Syndrome Type A (MPS IIIA) After Treatment with ABO-102 Gene Therapy View Press Release View All Our inspiration Learn More Pipeline Our clinical-stage therapies are designed to deliver functional copies of affected genes to cells using gene transfer technologies. Explore R&D EB-101 In Phase 3 development. Autologous gene-corrected cell therapy for patients with RDEB. Learn More ABO-102 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type A (MPS IIIA). Learn More ABO-101 In Phase 1/2 development. One-time, AAV-based gene therapy for patients with Sanfilippo syndrome type B (MPS IIIB). Learn More Manufacturing at The Elisa Linton Center for Rare Disease Therapies Learn More
